Braxia Scientific: Shareholder Votes and Strategic Direction

Braxia Scientific Corp. ("Braxia Scientific"), a medical research company specializing in innovative ketamine treatments for depression and related disorders, recently announced the voting results from its Annual General and Special Meeting of Shareholders. The meeting, held on October 28, 2021, saw a turnout of 11.77% of the issued and outstanding common shares represented either in person or by proxy.

The Company proposed four nominees for the Board of Directors, and all were elected with the following shareholder support:
- Dr. Roger McIntyre: 99.98%
- Dr. Ryan Yermus: 99.98%
- Dr. David Mischoulon: 99.98%
- Dr. Michael Van Ameringen: 99.98%

Shareholders also approved the following resolutions:
- Election of Directors: 99.98%
- Appointment of Auditors: 99.98%
- Approval of the Company's Stock Option Plan: 99.97%
- Approval of the Company's Restricted Share Unit Plan: 99.97%


The voting results indicate strong shareholder support for the Company's proposed resolutions and board nominees. The high approval rates suggest that shareholders have confidence in the Company's management and strategic direction. The approval of the stock option and restricted share unit plans may also indicate shareholder support for the Company's compensation strategies to attract and retain talent.


Institutional investors and retail investors voted similarly, with both groups showing strong support for the Company's proposals. The voting results align with previous years' shareholder meetings, where Braxia Scientific has consistently received high approval rates for its resolutions and board nominees.

The voting results highlight shareholder confidence in the Company's management and strategy, which may bode well for Braxia Scientific's future plans. The Company's focus on innovative ketamine treatments for mental health disorders positions it well in the growing market for alternative treatments. With strong shareholder support, Braxia Scientific can continue to execute its strategic plans and drive growth in the medical research sector.